Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Commutability of proficiency testing material containing tobramycin: a study within the framework of the Dutch Calibration 2.000 project.
Robijns K, Boone NW, Jansen RT, Kuypers AW, Neef C, Touw DJ. Robijns K, et al. Among authors: boone nw. Clin Chem Lab Med. 2017 Feb 1;55(2):212-217. doi: 10.1515/cclm-2015-1254. Clin Chem Lab Med. 2017. PMID: 27487495
A Multilaboratory Commutability Evaluation of Proficiency Testing Material for Carbamazepine and Valproic Acid: A Study Within the Framework of the Dutch Calibration 2000 Project.
Robijns K, Boone NW, Kuypers AW, Jansen RT, Neef C, Touw DJ. Robijns K, et al. Among authors: boone nw. Ther Drug Monit. 2015 Aug;37(4):445-50. doi: 10.1097/FTD.0000000000000164. Ther Drug Monit. 2015. PMID: 25525758
Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
Boone NW, van Leeuwen RW. Boone NW, et al. Clin Ophthalmol. 2012;6:145. doi: 10.2147/OPTH.S28071. Epub 2012 Jan 19. Clin Ophthalmol. 2012. PMID: 22291455 Free PMC article. No abstract available.
The nocebo effect challenges the non-medical infliximab switch in practice.
Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, Janknegt R, Peeters R, Landewé RBM, Winkens B, van Bodegraven AA. Boone NW, et al. Eur J Clin Pharmacol. 2018 May;74(5):655-661. doi: 10.1007/s00228-018-2418-4. Epub 2018 Jan 24. Eur J Clin Pharmacol. 2018. PMID: 29368188 Free PMC article.
Non-specific treatment effects and the patient perception of costly drug therapy.
Boone NW. Boone NW. Eur J Clin Pharmacol. 2018 Oct;74(10):1363. doi: 10.1007/s00228-018-2491-8. Epub 2018 May 31. Eur J Clin Pharmacol. 2018. PMID: 29855656 No abstract available.
Editorial: nocebo effect and switching to biosimilars.
van Bodegraven AA, Boone NW. van Bodegraven AA, et al. Among authors: boone nw. Aliment Pharmacol Ther. 2018 Mar;47(6):850-851. doi: 10.1111/apt.14509. Aliment Pharmacol Ther. 2018. PMID: 29446141 Free article. No abstract available.
Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs).
Boone NW, Teeuwisse P, van der Kuy PH, Janknegt R, Landewé RB. Boone NW, et al. Springerplus. 2015 Aug 28;4:462. doi: 10.1186/s40064-015-1247-5. eCollection 2015. Springerplus. 2015. PMID: 26339563 Free PMC article.
Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
Boone NW, Sepriano A, van der Kuy PH, Janknegt R, Peeters R, Landewé RBM. Boone NW, et al. RMD Open. 2019 Jan 22;5(1):e000836. doi: 10.1136/rmdopen-2018-000836. eCollection 2019. RMD Open. 2019. PMID: 30740244 Free PMC article.
Less is more: a cost benefit analysis of a changed posology for nivolumab.
Boone NW, van Bodegraven AA. Boone NW, et al. Eur J Clin Pharmacol. 2020 May;76(5):739-740. doi: 10.1007/s00228-020-02839-7. Epub 2020 Jan 28. Eur J Clin Pharmacol. 2020. PMID: 31993685 No abstract available.
Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice.
Boone NW, Sepriano A, van der Kuy PH, Janknegt R, Peeters R, Landewé RBM. Boone NW, et al. RMD Open. 2019 Nov 28;5(2):e001050. doi: 10.1136/rmdopen-2019-001050. eCollection 2019. RMD Open. 2019. PMID: 31908842 Free PMC article.
11 results
Jump to page
Feedback